Plasma brain natriuretic Peptide as a predictive marker of early recurrent stroke in cardioembolic stroke patients.

K. Shibazaki,K. Kimura,Junya Aoki,Kenichiro Sakai,Naoki Saji,J. Uemura

DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.06.003

2014-11-01

Abstract:

What problem does this paper attempt to address?

The evaluation of reflective learning from the nursing student's point of view: A mixed method approach.

Rosario Fernández-Peña,C. Fuentes-Pumarola,M. C. Malagón-Aguilera,Anna Bonmatí‐Tomas,Cristina Bosch-Farré,David Ballester-Ferrando

DOI: https://doi.org/10.1016/j.nedt.2016.05.005

IF: 3.906

2016-09-01

Nurse Education Today

Abstract:
Atypical Hemolytic Uremic Syndrome in a Pregnant Patient with a Thrombomodulin Gene Variant Treated with Plasma Exchange and Eculizumab

Lakshmi Kannan

DOI: https://doi.org/10.12659/AJCR.938896

2023-04-30

Abstract:BACKGROUND Hemolytic uremic syndrome (HUS) includes the triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. The atypical form of HUS is a rare disease characterized by complement overactivation, and it can be from genetic or acquired causes. Genetic causes involve mutation in one of the factors in the alternative complement pathway or inhibitors. Malignant hypertension and pregnancy are the most important acquired causes. The optimal management of patients with aHUS is with eculizumab, which is recombinant antibody against human complement component C5. CASE REPORT This report describes the case of a 25-year-old woman with frequent hospitalizations for poorly controlled hypertension who presented at 20 weeks of gestation with headache, vomiting, and a blood pressure of 230/126 mmHg. The patient had acute kidney injury with hematuria and proteinuria, and kidney biopsy showed hypertensive arteriolar nephrosclerosis and fibrinoid arteriolar necrosis consistent with thrombotic microangiopathy. Further work-up with a genetic panel showed heterozygosity for the thrombomodulin (THBD) gene. She was started on treatment with plasma exchange and eculizumab, a recombinant monoclonal antibody that inhibits terminal complement activation at the C5 protein. The patient responded well to the treatment at the time of her initial outpatient follow-up. CONCLUSIONS This case shows the potential of severe renal manifestation of aHUS, and the need for a kidney biopsy in cases of severe uncontrolled hypertension presenting with kidney injury. If evidence of aHUS is found, prompt treatment with plasma exchange and eculizumab should be initiated.
Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis

Patricia Ramos Mayordomo,Marta Capilla Díez,Danay Areli Ticona Espinoza,María Verónica Torres Jaramillo,Nathalie Martínez Tejeda,Thalia Gloria Ticona Espinoza,Cristina Colmenero Calleja,Virginia Fraile Gutiérrez

DOI: https://doi.org/10.1515/almed-2024-0053

2024-04-26

Abstract:Objectives: Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic hemolytic anemia and target organ damage. Pregnancy is associated with several forms of TMA, including preeclampsia (PE), HELLP syndrome, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). When HUS is secondary to a deregulation of the alternative complement pathway, it is known as atypical HUS (aHUS). Differential diagnosis is challenging, as these forms share clinical characteristics. However, early diagnosis is crucial for a specific treatment to be established and improve prognosis. Case presentation: We present the case of a 43 year-old primiparous woman admitted to hospital for an urgent C-section at 33 gestational weeks due to a diagnosis of severe preeclampsia and fetal distress. In the immediate postpartum, the patient developed acute liver failure and anuric renal failure in the context of the HELLP syndrome, anemia, thrombocytopenia, arterial hypertension (HTN) and neurological deficit. TMA study and differential diagnosis confirmed pregnancy-associated aHUS. Treatment with eculizumab was initiated, with good response and progressive improvement of clinical and analytical parameters. Conclusions: aHUS is a rare multifactorial disease that used to be associated with high mortality rates before the advent of eculizumab. Due to challenging diagnosis, the clinical laboratory plays a major role in the differential diagnosis and management of the disease.
Exacerbation‐prone asthma–intrinsic to severe disease or a unique phenotype?

J. Corren

DOI: https://doi.org/10.1111/cea.12256

2014-02-01

Abstract:
#5113 THE MULTIVERSE OF PREGNANCY-ASSOCIATED AHUS: TRIGGERS, TIMING AND OUTCOMES – A SINGLE CENTER EXPERIENCE

Andrea Spasiano,Daniela Palazzetti,Anna Petrosino,Chiara Tacente,Gianmarco De Luca,Alessandro Naticchia,Francesca Bruno,Rocco Baccaro,Pietro Manuel Ferraro,Giuseppe Grandaliano

DOI: https://doi.org/10.1093/ndt/gfad063c_5113

IF: 7.1857

2023-06-01

Nephrology Dialysis Transplantation

Abstract:Abstract Background and Aims Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by dysregulation of the alternative pathway of complement, characterized by hemolytic microangiopathic anemia, thrombocytopenia and acute kidney injury. Incidence is ∼ 0.23 per year per million people and about 7% of aHUS diagnoses occur in the setting of pregnancy, determining the so-called “pregnancy associated aHUS” (PaHUS). It could occur during gestation, in the immediate postpartum period or up to 12 weeks after delivery. Maternal exposure to semiallogenic fetoplacental material represents a complement triggering condition, worsened over gestation, with a climax at the delivery. Despite the attempt of solute and membrane regulators to mitigate the immune overactivation, an exaggerated inflammatory response, a decrease in the amount of regulatory proteins or some inherited or de novo mutations in complement factors’ genes, predispose to complement dysregulation. Its diagnosis is often delayed due to a multiform manifestation and similarity with HELLP syndrome or other thrombotic microangiopathy disorders (TMA), such as thrombotic thrombocytopenic purpura. It results in a delayed treatment, consequently threatening mother and fetus life. PaHUS is linked to high rates of end stage kidney disease, nearly achieving 78% at 24 months’ postpartum without eculizumab therapy. Indeed, anti-C5 therapy is effective and universally considered the best choice to treat aHUS. Method In this case series, we report our experience about the management of PaHUS during the last 2 years. An internal hospital protocol points out suspected TMA patients semi-automatically, thanks to a structured teamwork among emergency department and laboratory, hematology, nephrology and intensive care units. Treatment protocol applied was standard eculizumab induction therapy for all cases. All data will be presented as mean ± SD, medians and percentages. Results From January 2020 to December 2022, we diagnosed 14 patients with aHUS in our hospital. Five (35.7%) of them faced this disorder during the third trimester of pregnancy. Among different possible triggers, we observed postpartum hemorrhage, intrauterine fetal death, uterine atony and abruptio placentae with spontaneous abortion. Only 1 out of 5 reported a positive genetic test, showing a heterozygous missense mutation in CD46 of uncertain significance (Table 1). Due to the outbreak of peripartum complications, all patients were diagnosed between 1 and 5 days (2.2 days ± 1.6, median 2.0 days). After the diagnosis, we started the treatment within 27.6 ± 15.2 hours (median 24.0 hours). Only one patient needed acute renal replacement therapy. All our patients gradually recovered a normal kidney function, without any further complications. Serum creatinine normalized in 16.4 ± 9.5 days (median 20.0 days) (Fig. 1A), hemoglobin values improved in 35.2 ± 7.33 days (median 34.0 days) (Fig. 1B) and platelets returned in range in 8 ± 5 days (median 7.0 days) (Fig. 1C). Moreover, LDH and haptoglobin levels, chosen as hemolysis markers, restored in an average time of 29.8 ± 5.0 (median 30.0 days) (Fig. 1D) and 19.8 ± 14.3 days (median 10.0 days), respectively. Conclusion Nowadays, our patients have normal kidney function, treated with C5-inhibitors twice a month in outpatient setting. Moreover, one patient suspended infusion with close monitoring. Hence, we hope that these clinical records could help to improve the awareness of this manifold syndrome and to emphasize the importance of an early diagnosis and a timely treatment with eculizumab to guarantee full pregnants’ recovery.

urology & nephrology,transplantation
Silicon photonic crystal nanocavity-coupled waveguides for error-corrected optical biosensing.

Sudeshna Pal,E. Guillermain,R. Sriram,B. Miller,P. Fauchet

DOI: https://doi.org/10.1016/j.bios.2011.03.024

2011-06-15

Abstract:
Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis

Fadi Fakhouri,Marie Scully,Gianluigi Ardissino,Imad Al-Dakkak,Benjamin Miller,Eric Rondeau

DOI: https://doi.org/10.1007/s40620-021-01025-x

IF: 4.4061

2021-04-07

Journal of Nephrology

Abstract:Abstract Background Atypical hemolytic uremic syndrome (aHUS) is a rare disease in which uncontrolled terminal complement activation leads to systemic thrombotic microangiopathy (TMA). Pregnancy can trigger aHUS and, without complement inhibition, many women with pregnancy-triggered aHUS (p-aHUS) progress to end-stage renal disease (ESRD) with a high risk of morbidity. Owing to relatively small patient numbers, published characterizations of p-aHUS have been limited, thus the Global aHUS Registry (NCT01522183, April 2012) provides a unique opportunity to analyze data from a large single cohort of women with p-aHUS. Methods The demographics and clinical characteristics of women with p-aHUS ( n = 51) were compared with those of women of childbearing age with aHUS and no identified trigger (non-p-aHUS, n = 397). Outcome evaluations, including renal survival according to time to ESRD, were compared for patients with and without eculizumab treatment (a complement C5 inhibitor) in both aHUS groups. Results Baseline demographics and clinical characteristics were broadly similar in both groups. The proportion of women with p-aHUS and non-p-aHUS with pathogenic variant(s) in complement genes and/or anti-complement factor H antibodies was similar (45% and 43%, respectively), as was the proportion with a family history of aHUS (12% and 13%, respectively). Eculizumab treatment led to significantly improved renal outcomes in women with aHUS, regardless of whether aHUS was triggered by pregnancy or not: adjusted hazard ratio for time to ESRD was 0.06 ( p = 0.006) in the p-aHUS group and 0.20 ( p < 0.0001) in the non-p-aHUS group. Conclusion Findings from this study support the characterization of p-aHUS as a complement-mediated TMA. Graphic abstract

urology & nephrology
Super-Resolution Microscopy in Studying the Structure and Function of the Cell Nucleus

S. Ryabichko,A. Ibragimov,L. A. Lebedeva,E. Kozlov,Y. Shidlovskii

DOI: https://doi.org/10.32607/2075-8251-2017-9-4-42-51

2017-10-01

Acta Naturae

Abstract:In recent decades, novel microscopic methods commonly referred to as super- resolution microscopy have been developed. These methods enable the visualization of a cell with a resolution of up to 10 nm. The application of these methods is of great interest in studying the structure and function of the cell nucleus. The review describes the main achievements in this field.
Etiology and outcomes: Thrombotic microangiopathies in pregnancy

Marie Scully,Lucy Neave

DOI: https://doi.org/10.1016/j.rpth.2023.100084

2023-02-13

Abstract:A State of the Art lecture titled "Etiology and Outcomes of Thrombotic Microangiopathies in Pregnancy" was presented at the International Society on Thrombosis and Haemostasis Congress in 2022. First, it is important to understand changes in laboratory parameters in normal pregnancy, including complement levels, specifically the increase in C3, C4, C3a, and C4a throughout pregnancy. Complement is critical in normal pregnancy for implantation and for placental development. Complement-mediated hemolytic uremic syndrome (CM-HUS) and thrombotic thrombocytopenic purpura (TTP) can present anytime from the first trimester to the postpartum period. In comparison, Thrombotic microangiopathies specific to pregnancy, such as preeclampsia (PET) or hemolysis, elevated liver enzymes, and low platelets (HELLP), present from the second trimester. C5b-9 deposition (following terminal complement pathway activation) is demonstrated in CM-HUS cases, and in HELLP and few PET cases. PET can also be confirmed and related to severity using soluble fms-like tyrosine kinase-1/placental growth factor ratios. Diagnosis of CM-HUS and TTP in pregnancy can be further complicated by clinical overlap at presentation with PET or occasionally HELLP. Management is aided by ADAMTS-13 analysis to confirm or exclude TTP. Treatment of CM-HUS, in conjunction with supportive care, is complement inhibitor therapy (eculizumab or ravulizumab). Acute TTP requires standard therapy, but caplacizumab should be avoided. Confirmation of congenital or immune subtypes informs care in subsequent pregnancies. Finally, we summarize relevant new data on this topic presented during the 2022 International Society on Thrombosis and Haemostasis Congress.
Pregnancy‐associated atypical hemolytic uremic syndrome. Case report

Christopher Barrera‐Hoffmann,Yadira Mariaca‐Ortíz,Josué Giovani Ruiz‐Villa,Lesllie Eugenia Cuevas‐Cruz,María del Rosario López‐Mendoza,Jesús Carlos Briones‐Garduño

DOI: https://doi.org/10.1111/jog.15958

2024-05-10

Journal of Obstetrics and Gynaecology Research

Abstract:Pregnancy‐associated atypical hemolytic uremic syndrome (P‐aHUS) is a rare disease. There are only few reports in the literature, and most are in the puerperium period. It is a thrombotic microangiopathy (TMA) characterized for microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction. We report the case of a pregnant patient at 26.3 gestation weeks, who developed clinical features of TMA, neurological alterations, and septic shock; then after fetus and placental delivery, no clinical improvement was observed; a diagnostic protocol was performed due to suspicion of P‐aHUS, showing improvement after the plasma exchange sessions and eculizumab. We present here a brief review of the case since it is an entity that needs to be suspected during pregnancy when TMA features and requires an immediate diagnosis to provide timely treatment.

obstetrics & gynecology
No HELLP at all: Post-partum atypical hemolytic uremic syndrome treated with Eculizumab: A case report

Blerina Asllanaj,Nazanin Sheikhan,Elizabeth Benge,Jordan Valenta,Rosaly Diaz

DOI: https://doi.org/10.30574/wjarr.2022.15.2.0585

2022-08-30

World Journal of Advanced Research and Reviews

Abstract:Atypical hemolytic uremic syndrome (aHUS) is a rare condition among thrombotic microangiopathies (TMA). Pregnancy is a known precipitating factor of complement mediated TMA. The occurrence of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury presents diagnostic and therapeutic challenges. Diverse causes include hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) in pregnant women. In pregnancy or postpartum, the occurrence of aHUS is a critical complication requiring urgent diagnosis and treatment. aHUS is considered to be the result of the underlying condition, with the understanding that therapy is focused on the underlying condition. Five documented cases of pregnancy-associated aHUS treated with Eculizumab have been reported, making the condition extremely rare. We present the case of a pregnant woman with HELLP syndrome induced aHUS. The patient presented with evidence of dysregulation of the complement system and renal insufficiency. Since the initiation of Eculizumab, a C5 complement inhibitor, the development of renal insufficiency diminished and the patient became dialysis independent.
Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum

Ming Y. Lim,Mouhamed Yazan Abou-Ismail,D. Ware Branch

DOI: https://doi.org/10.1097/aog.0000000000005024

2022-12-22

Obstetrics and Gynecology

Abstract:The most common thrombotic microangiopathy (TMA) of pregnancy is the well-recognized syndrome of preeclampsia with hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. However, rare TMAs, including thrombotic thrombocytopenic purpura, complement-mediated hemolytic-uremic syndrome, and catastrophic antiphospholipid syndrome, may occur during pregnancy or postpartum and present with features similar to those of preeclampsia with severe features. Early recognition and treatment of these infrequently encountered conditions are key for avoiding serious maternal morbidities with long-term sequelae and possible maternal or fetal death. Differentiating between preeclampsia with severe features and these rare TMAs is diagnostically challenging as there is significant overlap in their clinical and laboratory presentation. Given the rarity of these TMAs, high-quality evidence-based recommendations on diagnosis and management during pregnancy are lacking. Using current objective information and recommendations from working groups, this report provides practical clinical approaches to diagnose and manage these rare TMAs. This report also discusses how to manage individuals with a history of these rare TMAs who are planning to conceive. To optimize favorable outcomes, a multidisciplinary approach including obstetricians, maternal-fetal medicine specialists, hematologists, and nephrologists alongside close clinical and laboratory monitoring is vital.

obstetrics & gynecology
Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab

Justin Chua,Kathy Paizis,Simon Z He,Peter Mount

DOI: https://doi.org/10.1111/nep.12935

Abstract:Background: Atypical haemolytic uraemic syndrome (aHUS) is a rare condition with the triad of microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury. Other conditions that present in a similar manner peri-partum include thrombotic thrombocytopaenic purpura, and pregnancy associated conditions including HELLP syndrome (haemolysis, elevated liver enzymes and low platelets), severe pre-eclampsia and less commonly acute fatty liver of pregnancy. Case reports: We describe two cases of suspected aHUS, who presented post-partum with foetal death-in-utero at 33 and 37 weeks respectively. Both presented with the triad features of aHUS but had considerably different clinical courses. The first case required a prolonged ICU admission, needed intubation for neurological deterioration and dialysis for acute kidney injury, and developed complications including acute liver failure, septic shock, pancreatitis, and ischaemic colitis. Initial ADAMSTS13 activity was borderline-low (10.3%) and normal on repeat testing (42.6%), and there was no peri-partum pre-eclampsia. The other case remained clinically stable throughout her admission with creatinine peaking at 495, not requiring dialysis, minor liver transaminases derangement and was discharged after a week. Her ADAMSTS13 activity was normal (62%), and her pregnancy was complicated by peri-partum pre-eclampsia. Both eventually had a reduction in haemolysis with rapid and sustained reduction in LDH and normalised platelet counts, and complete recovery of renal function whilst receiving eculizumab therapy. Conclusions: It can be difficult to distinguish aHUS from other causes in peri-partum patients presenting with features of microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury, and often, aHUS can be precipitated by pregnancy. In the setting of the clinical urgency to treat aHUS early with eculizumab, this presents a diagnostic challenge, as confirmatory tests for aHUS are not immediately available.
HELLP Syndrome and Differential Diagnosis with Other Thrombotic Microangiopathies in Pregnancy

Stefano Raffaele Giannubilo,Daniela Marzioni,Giovanni Tossetta,Andrea Ciavattini

DOI: https://doi.org/10.3390/diagnostics14040352

IF: 3.6

2024-02-07

Diagnostics

Abstract:Thrombotic microangiopathies (TMAs) comprise a distinct group of diseases with different manifestations that can occur in both pediatric and adult patients. They can be hereditary or acquired, with subtle onset or a rapidly progressive course, and they are particularly known for their morbidity and mortality. Pregnancy is a high-risk time for the development of several types of thrombotic microangiopathies. The three major syndromes are hemolysis, elevated liver function tests, and low platelets (HELLP); hemolytic uremic syndrome (HUS); and thrombotic thrombocytopenic purpura (TTP). Because of their rarity, clinical information and therapeutic results related to these conditions are often obtained from case reports, small series, registries, and reviews. The collection of individual observations, the evolution of diagnostic laboratories that have identified autoimmune and/or genetic abnormalities using von Willebrand factor post-secretion processing or genetic–functional alterations in the regulation of alternative complement pathways in some of these TMAs, and, most importantly, the introduction of advanced treatments, have enabled the preservation of affected organs and improved survival rates. Although TMAs may show different etiopathogenesis routes, they all show the presence of pathological lesions, which are characterized by endothelial damage and the formation of thrombi rich in platelets at the microvascular level, as a common denominator, and thrombotic damage to microcirculation pathways induces "mechanical" (microangiopathic) hemolytic anemia, the consumption of platelets, and ischemic organ damage. In this review, we highlight the current knowledge about the diagnosis and management of these complications during pregnancy.

medicine, general & internal
Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome

Mehmet Nuri Duran,Fatma Beyazit,Mesut Erbaş,Onur Özkavak,Celal Acar,Serkan Bakirdogen

DOI: https://doi.org/10.1177/1753495X211019902

Abstract:Pregnancy-associated atypical haemolytic uraemic syndrome is a rare and potentially lethal complement-mediated disorder. It can mimic preeclampsia, gestational hypertension, thrombotic thrombocytopenic purpura and hemolysis, elevated liver enzymes and low platelets syndrome. Thus, it can be hard to distinguish pregnancy-associated atypical haemolytic uraemic syndrome from other causes in peri/post-partum women presenting with features of microangiopathic haemolytic anemia, thrombocytopenia and acute kidney injury. We present a case of a 35-year-old woman in her third pregnancy at 32 weeks' gestation who underwent caesarean section due to fetal distress. She developed severe renal impairment, thrombocytopenia and neurologic symptoms within 24 hours after delivery. A diagnosis of pregnancy-associated atypical haemolytic uraemic syndrome was provided, and treatment with plasma therapy followed by eculizumab was initiated. A rapid improvement of both clinical and laboratory parameters was observed. This case demonstrates the significance of early initiation of anti-complement therapy to prevent irreversible renal damage and possible death in women with pregnancy-associated atypical haemolytic uraemic syndrome.
Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

Keval Yerigeri,Saurav Kadatane,Kai Mongan,Olivia Boyer,Linda L G Burke,Sidharth Kumar Sethi,Christoph Licht,Rupesh Raina,Linda LG Burke

DOI: https://doi.org/10.2147/JMDH.S245620

2023-08-05

Journal of Multidisciplinary Healthcare

Abstract:Keval Yerigeri, 1 Saurav Kadatane, 2 Kai Mongan, 3 Olivia Boyer, 4 Linda LG Burke, 5 Sidharth Kumar Sethi, 6 Christoph Licht, 7 Rupesh Raina 8 1 Department of Internal Medicine-Pediatrics, Case Western Reserve University/The MetroHealth System, Cleveland, OH, USA; 2 Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 3 Northeast Ohio Medical University, Rootstown, OH, USA; 4 Department of Pediatric Nephrology, Dialysis and Transplantation, Necker-Enfants Malades Hospital, MARHEA reference Center, Imagine Institute, Paris Cité University, Paris, France; 5 aHUS Global Advocate with aHUS Alliance, Cape Elizabeth, ME, USA; 6 Department of Pediatric Nephrology and Pediatric Renal Transplant Medicine, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India; 7 Department of Paediatrics, Division of Nephrology, University of Toronto, Toronto, ON, Canada; 8 Division of Pediatric Nephrology, Akron Children's Hospital, Akron, OH, USA Correspondence: Rupesh Raina, Tel +1 216 401 7894, Email Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) defined by the triad of hemolytic anemia, thrombocytopenia, and acute kidney injury. Microthrombi develop in the glomerular capillaries secondary to endothelial damage and exert shear stress on red blood cells, consume platelets, and contribute to renal dysfunction and failure. Per current understanding of pathophysiology, HUS is classified into infectious, secondary, and atypical disease. The most common etiology is infectious sequelae of Shiga toxin-producing Escherichia coli (STEC); other causative organisms include shigella and salmonella. Secondary HUS arises from cancer, chemotherapy, solid organ and hematopoietic stem cell transplant, pregnancy, or autoimmune disorders. Primary atypical hemolytic-uremic syndrome (aHUS) is associated with genetic mutations in complement and complement regulatory proteins. Under physiologic conditions, complement regulators keep the alternative complement system continuously active at low levels. In times of inflammation, mutations in complement-related proteins lead to uncontrolled complement activity. The hyperactive inflammatory state leads to glomerular endothelial damage, activation of the coagulation cascade, and TMA findings. Atypical hemolytic-uremic syndrome is a rare disorder with a prevalence of 2.21 to 9.4 per million people aged 20 years or younger; children between the ages of 0 and 4 are most affected. Multidisciplinary health care is necessary for timely management of its extra-renal manifestations. These include vascular disease of the heart, brain, and skin, pulmonary hypertension and hemorrhage, and pregnancy complications. Adequate screening is required to monitor for sequelae. First-line treatment is the monoclonal antibody eculizumab, but several organ systems may require specialized interventions and coordination of care with sub-specialists. Keywords: atypical hemolytic uremic syndrome, eculizumab, plasma exchange, complications, extra-renal manifestations Thrombotic microangiopathies (TMA) are a constellation of disorders characterized by injury to the endothelium of micro-vessels, resulting sequentially in platelet activation, micro-thrombosis, Coombs-negative hemolytic anemia, and thrombocytopenia. 1,2 The differential for TMA disorders is demonstrated in Figure 1. The development of microthrombi can lead to small vessel occlusion, downstream ischemia, and end-organ damage. TMA encompasses thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), and atypical hemolytic-uremic syndrome (aHUS). The overlap between these conditions makes a definitive diagnosis challenging and demands extensive work-up. 3 Figure 1 The differential diagnosis for thrombotic microangiopathies (TMAs) is broad and includes infection-associated hemolytic uremic syndrome (HUS), atypical hemolytic-uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP). The most common infectious source of HUS is Shiga-toxin producing Escherichia coli (STEC). Activity of the ADAMTS13 enzyme is a key diagnostic variable. The goals of this review are to provide an update on the genetic mechanisms behind complement dysfunction in aHUS, detail organ-specific clinical manifestations, and outline current management strategies. Multi-organ disease involvement belies the need for a multidisciplinary approach to management. The complement system has three pathways: classical, alternative, and lectin-binding. These pathways have different initial steps but converge on forming C3 convertase to propagate complement activity and destroy path -Abstract Truncated-

health care sciences & services
Isolation and identification of a novel thermo-alkaline, thermostable, SDS andchelator resistant amylase producing Anoxybacillus sp. IB-A from hot springof Bakreswar, West Bengal (India): First report

Ipsit Hauli,B. Sarkar,Trinetra Mukherjee,S. Mukhopadhyay

Abstract:Amylases are one of the most important enzymes in present-day biotechnology. The objective of this study was to isolate and identify a potential thermophilic amylase producing bacterial strain from hot spring of Bakreswar village, Suri, West Bengal (India). Among the few isolated amylolytic strains on starch agar medium, the strain IB-A showed best amylase activity. Phylogenetic analysis based on 16S rDNA sequence homology shows that the isolated strain belongs to the genus Anoxybacillus, and named as Anoxybacillus sp. IB-A. The optimum temperature and pH for amylase production was found to be 60°C at pH 9.0. Characterization of crude amylase showed its best activity at pH 9.0 and temperature 70°C, with a thermostability of 100% for 10 hours. Enzyme activity was considerably enhanced in the presence of Mo+2, K+, Mn+2, Cu+2 and Co+2. The most significant observation is that the enzyme not only retained cent percent activity in presence of 10 mM Hg+2 and Pb+2 but also increased activity over the control. Among the tested metal ions Zn+2 and Ni+2 showed slight inhibitory effect. The enzyme also showed its high stability and activity in presence of surfactants and chelators, such as SDS, EDTA. So our result showed that the enzyme is highly thermostable, thermo-alkaline and chelator resistant which makes it a suitable candidate for liquefaction of starch at high temperature, in detergent and textile industries. This one is the first report of isolating a potential amylase producing thermophilic Anoxybacillus sp. from hot spring of Bakreswar, West Bengal (India).
The favorable outcome of subsequent pregnancy in a patient with a history of obstetric atypical hemolytic uremic syndrome

Elena I. Prokopenko,Vera M. Guryeva

DOI: https://doi.org/10.18786/2072-0505-2022-50-023

2022-07-22

Almanac of Clinical Medicine

Abstract:Atypical hemolytic uremic syndrome (aHUS) is a severe life-threatening disease associated with uncontrolled activation of alternative complement pathway. Obstetric aHUS, which develops in pregnant women and puerperas, is characterized by a particularly severe course with multiple organ failure, high death risk and end-stage renal disease. The prognosis of patients with obstetric aHUS has changed dramatically after the introduction of eculizumab, a monoclonal antibody to C5 complement component, into clinical practice. With timely initiation of the complement blocking therapy, the patients would not only survive, but also completely restore the function of the affected organs. Naturally, the question arises on the possibility of repeated pregnancies in women with previous obstetric aHUS and on the strategy of pregnancy management. The paper describes a clinical case of successful treatment with eculizumab for obstetric aHUS in the third trimester of the first pregnancy in a young and previously healthy woman, and the management of her second pregnancy. A 23-year old woman at 35-36 weeks of her first pregnancy developed the clinical picture of obstetric thrombotic microangiopathy, which was interpreted as a manifestation of severe preeclampsia and HELLP syndrome. However, after an emergency surgical delivery, the patient's condition continued to deteriorate despite the plasma exchange procedure. After exclusion of the other causes of thrombotic microangiopathy, aHUS was diagnosed and treatment with eculizumab was started, which resulted in complete recovery. No aHUS-associated mutations were identified. The complement inhibitor treatment was discontinued after 12 months. Four years after the first birth, the patient had a second pregnancy after preconception planning. During pregnancy, the patient was closely monitored for a timely identification of potential complications and had prevention of placental complications with acetylsalicylic acid and low molecular weight heparin. No aHUS recurrence and/or other complications were observed, and the patient did not require treatment with eculizumab during pregnancy. Elective caesarean section was performed at 39 week of gestation. A healthy boy was born with a bodyweight of 3370 g, a height of 50 cm, and Apgar score 8-9. In women with obstetric aHUS history, a favorable outcome of repeated pregnancies is possible, in some cases even without any prophylactic use of complement-blocking therapy, provided that with complete remission of aHUS has been achieved, with close monitoring during gestation and prevention of placenta-associated complications.
Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement

Di Song,Xiao-juan Yu,Feng-mei Wang,Bing-ning Xu,Ying-dong He,Qian Chen,Su-xia Wang,Feng Yu,Wen-chao Song,Ming-hui Zhao

DOI: https://doi.org/10.1111/aji.12404

2015-01-01

American Journal of Reproductive Immunology

Abstract:ProblemPostpartum atypical hemolytic uremic syndrome (aHUS) is a life-threatening syndrome with unclear pathogenesis. The current study aimed to investigate the clinical and pathological features, complement activation status, and the genetic variations in a Chinese cohort of patients with renal biopsy-proven postpartum aHUS.Method of studyFive patients with postpartum aHUS were recruited. Renal biopsy specimens were examined and scored. Plasma levels of complements were detected, and coding sequences of complement regulators were screened. Anti-CFH/CFI autoantibodies were further detected.ResultsPatients with postpartum aHUS patients presented with severe clinical manifestations and renal involvement. The renal biopsies of the five patients showed typical features of thrombotic microangiopathies. The levels of the following complement components, C4d, Bb, C3a, C5a, and SC5b-9, were significantly elevated in patients with postpartum aHUS compared with normal non-pregnant controls. The plasma levels of CFH and CFI significantly decreased in patients with postpartum aHUS compared with normal pregnant women. Three CFH single nucleotide polymorphisms (SNPs) were identified in the five patients. Two patients presented with CFH autoantibodies.ConclusionPostpartum aHUS is a clinical syndrome with severe renal damage. Genetic deficiencies and autoantibodies of CFH may lead to alternative pathway overactivation and participated in the pathogenesis of postpartum aHUS.
Accuracy of ultrasound to MR registration of the knee

Pe Murtha,N. Watterson,C. Nikou,B. Jaramaz

DOI: https://doi.org/10.1002/rcs.170

2008-03-01

Abstract:Ultrasound‐based registration to 3D surfaces segmented from MR imaging is proposed as a non‐invasive alternative to point‐based registration for image‐guided surgery. By relying upon diagnostic MR imaging, the expense of additional CT imaging (and exposure to radiation) is avoided. The technique would enable navigation in arthroscopic and other minimally invasive procedures.

Plasma brain natriuretic Peptide as a predictive marker of early recurrent stroke in cardioembolic stroke patients.

The evaluation of reflective learning from the nursing student's point of view: A mixed method approach.

Atypical Hemolytic Uremic Syndrome in a Pregnant Patient with a Thrombomodulin Gene Variant Treated with Plasma Exchange and Eculizumab

Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis

Exacerbation‐prone asthma–intrinsic to severe disease or a unique phenotype?

#5113 THE MULTIVERSE OF PREGNANCY-ASSOCIATED AHUS: TRIGGERS, TIMING AND OUTCOMES – A SINGLE CENTER EXPERIENCE

Silicon photonic crystal nanocavity-coupled waveguides for error-corrected optical biosensing.

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis

Super-Resolution Microscopy in Studying the Structure and Function of the Cell Nucleus

Etiology and outcomes: Thrombotic microangiopathies in pregnancy

Pregnancy‐associated atypical hemolytic uremic syndrome. Case report

No HELLP at all: Post-partum atypical hemolytic uremic syndrome treated with Eculizumab: A case report

Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum

Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab

HELLP Syndrome and Differential Diagnosis with Other Thrombotic Microangiopathies in Pregnancy

Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management

Isolation and identification of a novel thermo-alkaline, thermostable, SDS andchelator resistant amylase producing Anoxybacillus sp. IB-A from hot springof Bakreswar, West Bengal (India): First report

The favorable outcome of subsequent pregnancy in a patient with a history of obstetric atypical hemolytic uremic syndrome

Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement

Accuracy of ultrasound to MR registration of the knee